Modern Dairies 1:1 bonus

At its upper circuit limit, the scrip touched its all-time high.

The dairy products maker announced a liberal bonus of 1:1 after market hours yesterday, 23 July 2007.

The scrip had touched a low of Rs 49.05 so far during the day. Its 52-week low was Rs 15 on 20 November 2006. At the current price of Rs 49.05, the scrip trades at a PE multiple of 15.67, based on the year ended March 2007 EPS of Rs 3.13.

The Modern Dairies scrip had gained 70.36% in the one month to 20 July 2007 versus the Sensex’s 7.35% gain. It added 101.13% in the past three months against the Sensex’s 12% return.

Satyam Computer plans for South Africa

Satyam Computer Services has announced strategic initiatives to strengthen its presence in South Africa.

The company is banking on a sizable number of contracts emanating from South Africa in the coming years and sees potential in providing IT solutions to the banking & financial, energy & utilities and government sectors.

As part of its global strategy, the company has also recruited and trained 50 South African technical graduates in the last one year. The first batch of 20 has been successfully deployed in projects in South Africa. Essentially an employment and skilled enablement program supporting the RSA’s BEEC, the company plans to hire almost 200 more local technical graduates, train them in India and bring them back to South Africa to associate with various customer projects.

Currently, the company serves 6 of the largest firms in the country, employs over 120 technical resources at customer locations and has offices in Johannesburg and Cape Town.

Buy Orchid + Unichem – Sharekhan Research

Sharekhan Equity Research is bullish on the prospects of Unichem Laboratoriess and Orchid Pharma. Sharekhan has a BUY recommendation with a price target of Rs 360 and Rs 375 respectively.

Unichem Laboratories:
For Q1FY2008 Unichem Labor atories (Unichem) has reported a sales growth of 12.1% to Rs153.5 crore, which is lower than expectation of Rs165 crore. The growth was subdued largely due to a sharp 18.8% decline in the company’s exports on account of the appreciation of the rupee.

Unichem’s strong brand building efforts, the continued momentum in its power brands and therapy focused marketing initiatives have caused the domestic formulation business to perform in the quarter. The revenues from this segment grew by an impressive 20.9% to Rs126.8 crore.

Unichem’s operating profit margin (OPM) expanded by 80 basis points to 22.4% in the quarter. The management has also indicated that such a high growth rate for this business might not be sustainable going forward. The company expects the growth to moderate in Q2FY2008, due to DPCO-related price cuts imposed on its largest brand Ampoxin towards the end of Q1FY2008. However, a conservative 11.5% growth in this business in FY2008E is doable and remain optimistic about the company’s ability to beat estimates.

At the current market price of Rs245, Unichem is trading at 8.6x its estimated FY2008 earnings. BuyUnichem, with a price target of Rs 360.

Orchid Pharmaceuticals:
Orchid’s top line grew by 18.1% year on year (yoy) to Rs238.2 crore in Q1FY2008. The top line growth was above estimates of Rs223.2 crore. Orchid’s operating profit margin (OPM) expanded by 110 basis points to 29.9% in Q1FY2008. On the other hand, the rising R&D costs (due to FTF filings) and increasing staff costs adversely impacted the margins. On a like-to-like basis (excluding the Rs10 crore incremental cost incurred on FTF filings), the margin expansion would have been even more robust at 530 basis points to 34.1%. Consequently, the operating profit grew by 22.8% to Rs71.2 crore in Q1FY2008.

At the current market price of Rs234, Orchid is quoting at 9.9x its estimated FY2009 earnings, on a fully diluted basis. In view of the bright prospects for the company, Sharekhan retains positive stance on the stock and maintain a Buy call with a price target of Rs 375.

Kotak has a price target of Rs 300 on Orchid Pharmaceuticals.

Dayim – Punj Lloyd Construction secures first order

Dayim Punj Lloyd Construction Contracting company, a joint venture company of Punj Lloyd, a global EPC services provider in energy and infrastructure domains, has secured its first order from Saudi Kayan Petrochemical company (SABIC) in KSA. The EPC value of the contract is US $ 79 million.

Under the contract, Dayim Punj Lloyd, on EPC basis, will construct 8 tanks for DM Water, Fire / Service Water, MEG and crude storage and one sphere for mixed butanes storage for offsite and utility of saudi kayan petrochemical complex at Jubail Industrial city, KS.

The major highlights of the project will be blast overpressure design for 5 tanks, FEA analysis for large bore nozzles for two tanks. Dayim Punj Lloyd will be constructing the largest tank – 71 dia x 18M high, cone roof carbon steel apart from three tanks of stainless steel 304L, max size 40.5M dia x 18 M high, cone roof. The work is scheduled to be completed by January 2009.

Dayim Punj Lloyd was formed with the joint venture of the company with His Royal Highness Prince Khalid Bin Bandar Bin Sultan (KBS), Kingdom of Saudi Arabia, in May 2006. Formed to identify new business opportunities in Saudi Arabia, it will serve as a powerful vehicle for both companies to expand roles in Saudi Arabia by offering the best of each company’s expertise and a dedicated service and support organization. Dayim Punj Lloyd is a jointly owned company in which the Punj Lloyds has 49% stake.

Loan Defaulters rise at ICICI Bank

ICICI Bank saw a sharp increase in its loan defaulters in the past quarter. Net non-performing assets [NPA] as a percentage of net customer assets increased from 0.98% at the end of March to 1.3% at the end of June. An increase of 0.32% in just 3 months is a cause of concern for many Banking analysts.

The stock price of ICICI Bank is on the rise mainly because of its subsidiaries – ICICI Insurance.

We personally don’t recommend ICICI Bank to our investors however, HDFC Bank in the Private Sector and Bank of Baroda under the public sector are our favorite picks. But certainly not at this level, BUY only when the market corrects.

UTI Bank raises US $ 1.050 Billion

UTI Bank has successfully priced its offering of 14.13 million GDRs, aggregating US $ 218.07 million. Each GDR, representing one underlying share, was priced at US $15.43 and will be listed on the London stock exchange. This represents a discount of 1.7% to the closing price of the bank’s GDR on 20 July 2007.

In addition, the bank has determined the issue price of the equity shares to be offered in the proposed qualified institutional placement (QIP) to be Rs 620 per share. The size of the QIP will be Rs 1,752 crore.

Further, the bank proposes to allot, on a preferential basis, 2,56,21,076 shares to its promoters at Rs 620 per share aggregating to Rs 1,588 crore.

1 4 5 6 7 8 16